Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018'

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F18%3A10384754" target="_blank" >RIV/00216208:11150/18:10384754 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/18:10384754

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.12386" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.12386</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ehf2.12386" target="_blank" >10.1002/ehf2.12386</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018'

Popis výsledku v původním jazyce

During the &apos;Heart Failure and World Congress on Acute Heart Failure 2018&apos;, many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the &apos;Heart Failure and World Congress on Acute Heart Failure 2018&apos;. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.

Název v anglickém jazyce

Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018'

Popis výsledku anglicky

During the &apos;Heart Failure and World Congress on Acute Heart Failure 2018&apos;, many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the &apos;Heart Failure and World Congress on Acute Heart Failure 2018&apos;. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ESC Heart Failure

ISSN

2055-5822

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

1083-1091

Kód UT WoS článku

000453876800012

EID výsledku v databázi Scopus

2-s2.0-85058899793